Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Haircafe is generally trusted for hair loss information, particularly for his evidence-based approach and recommendations of finasteride, dutasteride, and minoxidil. While some users appreciate his scientific focus and lack of product promotion, others criticize his dismissal of anecdotal evidence and certain biases.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

The user has been using finasteride and minoxidil for 18 months to address hair loss, with some concerns about thinning behind the hairline. They report side effects like lower libido and weaker erections but are unsure if these are due to the medication or other factors.

A 23-year-old male saw significant hair improvement after using topical minoxidil for five years and oral finasteride for one year. He is considering adding dutasteride weekly and continues using Head & Shoulders and Stiproxal for dandruff control.

A user stopped using minoxidil due to severe side effects and experienced rapid hair loss. They also tried finasteride and dutasteride but faced adverse reactions, leading them to consider accepting hair loss and exploring options like oral minoxidil or a hair transplant.

Hair loss treatments like finasteride, dutasteride, and minoxidil are discussed, with differing views on when to begin treatment. Some suggest early use, while others warn of hormonal side effects from starting too young.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.

A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.

A user shared their 16-year hair loss journey using finasteride and minoxidil, noting slow hair thinning despite a family history of severe balding. They switched from topical to oral minoxidil but stopped for personal reasons, experiencing no significant side effects from finasteride.

A serum with oleic and palmitoleic acids shows promise for hair regrowth in mice, but its effectiveness in humans is unproven. Minoxidil and finasteride remain the recommended treatments.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A person is struggling with hair loss and mental health issues, using treatments like dutasteride and minoxidil, and planning a hair transplant. They recently discovered their biological father is bald, causing additional stress, but are encouraged by others to focus on their treatment success and seek professional help for their mental health.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation discusses reducing scalp DHT to prevent hair loss, with a focus on using dutasteride, finasteride, and other treatments like RU58841 and minoxidil. It highlights the challenges of managing hair loss while on high testosterone levels, suggesting that dutasteride may be more effective than finasteride in such cases.

The user successfully maintained and regrew hair using finasteride for 11 years and oral minoxidil for 9 months, experiencing no significant side effects. They plan to continue these treatments to prevent hair loss.

A 19-year-old shares positive results after one year on finasteride, minoxidil, micro-needling, and Nizoral shampoo, reporting no side effects and improved hair density despite initial shedding. Others discuss mixed experiences with finasteride, some considering alternatives like dutasteride or hair transplants.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The user saw no hair regrowth after a year of using finasteride and dutasteride, only maintaining their current hair. Many recommend adding minoxidil for potential regrowth.

PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

The user successfully managed hair loss using Finasteride, Minoxidil, Ketoconazole shampoo, and a hair mask, experiencing significant hair growth and improved density. They attribute their success to consistency, improved nutrition, and a dedicated routine.

A 27-year-old shared a 90-day hair loss treatment update using Dutasteride, Minoxidil, Tretinoin, Ketoconazole, and microneedling, reporting positive results with improved hairline and density. They experienced minor side effects and noted a decrease in hair shedding.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

Dutasteride is more effective than Finasteride for hair loss, with similar safety profiles. Individual responses vary, and factors like Minoxidil use and age differences may influence results.

Minoxidil and finasteride are the main effective treatments for hair loss. RU58841 is discussed as a potential option but has concerns about safety and side effects.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

Way-316606 is considered a potential hair loss treatment but is avoided due to safety concerns and lack of research. Minoxidil and Finasteride are preferred as established treatments.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.